Your session is about to expire
← Back to Search
Pembrolizumab for Thyroid Cancer
Study Summary
This trial is testing a combination of two drugs to treat patients with advanced thyroid cancer.
- Unresectable Differentiated Thyroid Cancer
- Papillary Thyroid Carcinoma
- Thyroid Cancer
- Papillary Thyroid Cancer
- Thyroid Gland Carcinoma
- Differentiated Thyroid Gland Carcinoma
- Thyroid Gland Follicular Carcinoma
- Thyroid Gland Papillary Carcinoma
- Hurthle Cell Carcinoma
- Thyroid Carcinoma
- Papillary Carcinoma of the Thyroid Gland
Timeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Side effects data
From 2024 Phase 2 trial • 57 Patients • NCT03004183Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- Group 1: Treatment (lenvatinib, pembrolizumab)
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
How many healthcare facilities have been approved to conduct this investigation?
"Across the country, there are 7 medical centres taking part in this clinical trial. These include Memorial Sloan Kettering Cancer Center (New york), Ohio State University Comprehensive Cancer Center (Columbus) and Massachusetts General Hospital Cancer Centre (Boston). Additionally, 4 other sites are participating too."
To what diseases is the therapeutic Pembrolizumab typically prescribed?
"Pembrolizumab is an effective treatment for malignant neoplasms, inoperable melanoma, and microsatellite instability high cancers."
Is this experiment in need of new participants?
"Unfortunately, this particular medical trial is not presently seeking new participants. The protocol was originally uploaded on February 7th 2018 and last amended on January 5th 2022. If you are searching for other trials, there are currently 3443 opportunities to join a study related to thyroid (usp), as well as 1032 possibilities involving Pembrolizumab therapy."
Could you provide any details on prior research conducted in regards to Pembrolizumab?
"At present, 1032 Pembrolizumab trials are taking place with 134 of them being in the third phase. While Sacramento, California has a high concentration of studies for this drug, there exist 37061 clinics worldwide conducting research on it."
How many individuals have been accepted into this clinical trial thus far?
"Unfortunately, enrollment for this trial closed on January 5th 2022. The study was initially posted four years prior in February 2018. For those looking to participate in similar trials now, there are 3443 studies involving thyroid (usp) and 1032 Pembrolizumab-based studies actively recruiting patients at present."
Is Pembrolizumab a risk-free treatment option for patients?
"There is limited clinical evidence for Pembrolizumab's safety, resulting in it receiving a rating of 2."
Share this study with friends
Copy Link
Messenger